Swallowable capsule to unlock secrets of digestion after Weight-Loss surgery

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants eligible for inclusion in this Investigation have to meet all of the following criteria: 1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures 2. Age: 18-65 years Specific inclusion criteria for the different patient populations: Patients with obesity: 3. Body Mass Index: \> 30 kg/m2 Patients after bariatric surgery: 4. Surgery: at least one year after Roux-en-Y gastric bypass or sleeve gastrectomy Exclusion Criteria: Participants eligible for this Investigation must not meet any of the following criteria: 1. Patient has history of more than one bariatric surgery 2. Patient has a waist circumference \> 125.6 cm 3. Patient had gastrointestinal surgery in the past three months 4. Patient has a pacemaker, defibrillator, infusion pump, or other portable or implanted electromedical device 5. Patient had frequent exposure to X-rays in the past year 6. Patient has swallowing disorders, among others: dysphagia for food or pills, any oropharyngeal or oesophageal stricture, anxiety or functional abnormality 7. Patient has Crohn's disease or Diverticulitis 8. Patient has gastrointestinal strictures, fistulas or physiological/mechanical obstructions 9. Patient has gastric bezoar 10. Patient has a history of complex bowel resection or known abdominal adhesions 11. Patient has short bowel syndrome or ostomy 12. Patient has currently ongoing infections 13. Patient is planned to undergo usage of rectal foam/enema or treatment with adjuvant chemotherapy or radiotherapy 14. Patient is currently on parenteral diet 15. Patient is planned to undergo MRI procedure during usage of the wireless capsule 16. Patient is working in a professional healthcare facility (e.g. hospital, dental office, emergency room), military area (e.g. submarine, near radar installation), or heavy industrial area (e.g. power plants, automotive, mining, refineries) during the duration of the clinical investigation 17. Patient is pregnant, breastfeeding, actively trying to get pregnant or had recent childbirth in last 6 months 18. Patient cannot discontinue medication that affects gastrointestinal transit time and/or pH for at least 3 days before and during the study (and 4 weeks for weekly/long-acting GLP-1 analogues such as Saxenda, Ozempic, Wegovy, Mounjaro). This includes opioids (e.g., morphine, codeine), proton pump inhibitors (e.g., omeprazole, esomeprazole, pantoprazole), H2-receptor antagonists (e.g., cimetidine, famotidine), antacids, sucralfate, prokinetics (e.g., domperidone, metoclopramide), antidiarrheal agents (e.g., loperamide), antibiotics, probiotics and prebiotics. 19. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP.